Dariohealth Corp Stock Price, News & Analysis

DarioHealth Corp. (Nasdaq: DRIO) has secured a contract to provide its digital therapeutic solutions to eligible employees of a Fortune 500 technology company, starting January 1, 2021. This initiative aims to enhance the health management of chronic conditions like diabetes and hypertension. The contract is a significant milestone, showcasing Dario's strategic pivot towards the B2B2C market. The award highlights the competitive strength of Dario's digital care solution, which is already used by tens of thousands of consumers globally.

DarioHealth Corp. (NASDAQ: DRIO) presented a clinical study at the 20th Annual Diabetes Technology Society Meeting, highlighting significant improvements in diabetes management for adults aged 65 and older using its digital therapeutics platform. The study, involving 940 participants, showed a 13% reduction in average blood glucose levels over six months and a 38.1% drop in high blood glucose readings in subjects older than 65. Results indicated that outcomes for older adults were comparable or even better than those for younger participants, suggesting the platform's efficacy in managing chronic conditions.

DarioHealth Corp. (Nasdaq: DRIO) reported third-quarter 2020 revenues of $2.04 million, a 14.2% sequential increase. The company successfully penetrated the B2B2C market, establishing partnerships with Vitality Group and HMC Healthworks to expand its user base. Despite growth, gross profit fell by 37% to $549,000, and operating losses rose to $6.6 million, a 136% increase year-over-year. Cash reserves stand at $37 million, the highest in company history, supporting further investments. However, total operating expenses increased by 94.7%, primarily from marketing and compensation costs.

DarioHealth Corp. (Nasdaq: DRIO) announced it will release its financial results for Q3 2020, ending September 30, on November 12, 2020. A conference call is scheduled for 9:00 AM Eastern Time to discuss the results, featuring key executives including CEO Erez Raphael. The call will allow investors to gain insights into the company's financial performance and future outlook within the digital therapeutics market. A replay of the call will be accessible for two weeks following the event.

DarioHealth Corp. (Nasdaq: DRIO) announced its digital therapeutics solutions will be integrated into Vitality Group's new Gateway Flex offering. This partnership aims to provide employers with personalized healthcare solutions, enhancing employee engagement and cost-effectiveness. Dario's President, Rick Anderson, expressed confidence that this inclusion validates their digital therapeutic solutions. The partnership with Vitality Group, initiated in March 2020, aims to accelerate Dario's reach within the self-insured employer market, catering to the increasing demand for tailored health applications.

DarioHealth Corp. (Nasdaq: DRIO) has partnered with HMC HealthWorks to integrate its digital therapeutics solutions into HMC's care management programs. This collaboration enables HMC to offer DarioHealth's platform both independently and as part of its comprehensive health management services. DarioHealth aims to enhance chronic condition management for patients, validating its transition to a digital therapeutics provider. The partnership is expected to expand DarioHealth's distribution and build a client pipeline within HMC's extensive customer base.

DarioHealth Corp. (Nasdaq: DRIO) has appointed Eric Milledge as Chairman of its newly-formed Scientific Advisory Board (SAB). With over 34 years at Johnson & Johnson, Milledge brings extensive experience in pharmaceuticals and medical devices. His leadership roles included overseeing successful product launches and managing strategic hospital contracts. At DarioHealth, he will guide the SAB in enhancing digital therapeutics for chronic conditions, focusing on creating data supporting Dario's technology platform and expanding its offerings, like the integration of continuous glucose monitors.

DarioHealth Corp. (Nasdaq: DRIO) announced the acceptance of a poster for presentation at the virtual ADCES 2020 Annual Conference from August 13-16, 2020. The poster titled "Impact of Digital Management on Clinical Outcome in Patients with Chronic Conditions: Diabetes and Hypertension" highlights a study with 345 participants using Dario's digital therapeutics platform. Results show a 70% improvement in blood pressure and significant reductions in glucose levels among users diagnosed with diabetes. The findings position Dario's platform as a valuable tool for managing chronic diseases.